Shares of McKesson climbed after the drug distributor raised its fiscal-year guidance and reported strong sales growth during its fiscal second quarter. The stock was up 11%, at $610.99, in midday ...

U.S. stocks are ticking higher ahead of the Federal Reserve’s announcement coming later in the afternoon about what it will ...

TD Cowen analyst Charles Rhyee raised the firm’s price target on McKesson (MCK) to $651 from $642 and keeps a Buy rating on the shares.

Steve Baxter, an analyst from Wells Fargo, maintained the Hold rating on McKesson (MCK – Research Report). The associated price target ...

McKesson's earnings for its fiscal 2025 second quarter exceeded expectations, despite special charges that cut into net ...

McKesson (NYSE:MCK) reported better-than-expected second-quarter financial results on Wednesday. McKesson reported quarterly ...

Baird upgraded McKesson (NYSE:MCK) to outperform from neutral on Thursday, citing the updates the medical distributor gave ...

Fletcher-Hill sends the case to the jury for consideration. Baltimore alleges that the companies, McKesson and AmerisourceBergen, flooded the city with hundreds of millions of addictive pain pills ...

McKesson Corp (MCK) reports a 21% revenue increase and raises fiscal 2025 EPS guidance amid strategic expansions and ...

McKesson Corporation (NYSE: MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on McKesson’s Investor Relatio ...